Term
| cisplatin was discovered by applying an electrical field to- |
|
Definition
|
|
Term
| cisplatin is curative for- |
|
Definition
|
|
Term
cisplatin prolongs survival in?
also used in-4 |
|
Definition
ovarian cancer
head, neck, baldde,r lung |
|
|
Term
| what is the most freq used anticancer agent |
|
Definition
|
|
Term
| cisplatin has what toxicites- |
|
Definition
|
|
Term
| what other drugs have similar effiacy but less ADEs- |
|
Definition
|
|
Term
| how are platinum agents similar to alkylating |
|
Definition
| they are displaced by nucelophillic attacks to form covalent bonds |
|
|
Term
| what is the target of cisplatin |
|
Definition
|
|
Term
| what platinum drug is used with 5-FU for colon cancer |
|
Definition
|
|
Term
| why are trans-platinums inactive? |
|
Definition
| inability of the isomers to form DNA cross links |
|
|
Term
| Cisplatin formed more intra/interstrand cross links |
|
Definition
| 90% intrastrand (the trans-cis does inter) |
|
|
Term
carboplatin has less _ than cisplt? 3
has more?3 |
|
Definition
nephrotox (subst Cl), neurotox, N/V
stability and Pk predictability, marrow tox |
|
|
Term
the majority of adducts formed by cisplt and carboplat?
what is 2nd? |
|
Definition
G-G intrastrand XL 60%
A-G intrastrand XL |
|
|
Term
| what crosslinks account for cytotoxicity of platinum drugs? |
|
Definition
|
|
Term
diff in oxiplatin adducts from the tohers-2
what does it look like? |
|
Definition
hydrophobic
bulkier
DNA-protein XL (not strnad) |
|
|
Term
| consequences of DNA adduct-2 |
|
Definition
preoteins that participate in DNA rxns may become abnormal
processes controlled by proteins that recognize damaged DNA may be activated |
|
|
Term
cisplatin:
high/low prot bound?
half life?
eliminated thru? |
|
Definition
|
|
Term
|
Definition
|
|
Term
| look at slide 13 for a quick overview of cisplatin before test |
|
Definition
|
|
Term
| the diff in pk for cicplt and carboplt is |
|
Definition
| slower conversion of carboplatin to reactive subst |
|
|
Term
| disspaereance of platinum after carboplatin IVs is biphasic- occurs in _ min |
|
Definition
|
|
Term
| the clearence of carboplatin is closely related to? |
|
Definition
|
|
Term
| dosing of carboplatin is done by? |
|
Definition
|
|
Term
| carboplatin might have _ cleaving it to beocme more active in cells than IV |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| half life of inital and terminal phases for oxiplatin |
|
Definition
|
|
Term
| oxiplatin has prolonged retention where |
|
Definition
|
|
Term
| unlike cisplaitin, oxalpplatin doesnt accum after courses, this means: |
|
Definition
|
|
Term
| oxiplatin is excreted mianly by |
|
Definition
|
|
Term
| toxicites for oxiplatin are when its added to flurouricil : 3 |
|
Definition
| myleosuppre, stomatitis, neuropathy |
|
|
Term
| can prevent nephrotox of cisplatin with |
|
Definition
|
|
Term
| look at slide 18 for table overview of toxicite sof the agents! |
|
Definition
|
|
Term
| tumor resistance pathways-3 |
|
Definition
glutathione conjugation (by adenosine triphosphates)
metallothioneins and other sulfahydryls inactivate it
increase platinum-DNA adduct repair/ damage tolerance |
|
|
Term
| what are the sufahydrl groups used to prevetn platinum ADes-3 |
|
Definition
MESNA
sodium thiosulfate
amifostine |
|
|
